CML

Five-year OPTIC follow-up confirms benefit of response-based ponatinib dosing in chronic-phase CML

Five-year results from the OPTIC trial show that starting ponatinib at 45 mg then reducing to 15 mg upon response provides the best long-term efficacy and manageable safety in resistant CP-CML, particularly for T315I patients.

Optimizing CML Management: Clinical Synthesis of the ASC4OPT Study and the Allosteric Inhibition Paradigm